The 10 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 141.50, with a high estimate of 247.00 and a low estimate of 95.00. The median estimate represents a +39.97% increase from the last price of 101.09.
The current consensus among 11 polled investment analysts is to Buy stock in United Therapeutics Corp. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $2.79
Reporting Date Oct 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.